Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements.

AIDS. 1998 Sep 10;12(13):1581-90. Unique Identifier : AIDSLINE MED/98435805
Fahey JL; Taylor JM; Manna B; Nishanian P; Aziz N; Giorgi JV; Detels R; Department of Microbiology and Immunology, Center for; Interdisciplinary Research in Immunology and Disease, UCLA School; of Medicine, Los Angeles, California 90095-1747, USA.


Abstract: OBJECTIVE: To evaluate the prognostic significance for AIDS occurrence of plasma levels of immune activation markers in comparison with and in conjunction with HIV viral load and CD4 T-cell measurements. DESIGN: A retrospective analysis was conducted of three plasma activation markers, the soluble tumor necrosis factor (TNF) receptor II (TNF-RII), neopterin and soluble interleukin-2 receptor levels, and of CD4 T-cell levels and plasma HIV viral load. SUBJECTS: The participants were 659 men taking part in the University of California Los Angeles Multicenter AIDS Cohort Study who were HIV-seropositive but AIDS-free in 1985. MAIN OUTCOME MEASURE: Clinically defined AIDS within 3 years. Failure time statistical regression models for the time to development of AIDS were used to assess prognostic capacity of the parameters alone and in combination. RESULTS: All the markers had prognostic capability. The levels of the three plasma activation markers correlated well with each other (median r = 0.61). They related less well with HIV RNA plasma levels (median r = 0.50) and least well with CD4 cell levels (median r = 0.36). Furthermore, plasma marker levels were shown to be able to stratify patients for prognosis within all the major categories of CD4 T-cell and HIV RNA levels. CONCLUSIONS: Plasma levels of soluble TNF-RII and other soluble markers of immune activation have prognostic capabilities which are different from HIV and CD4 T-cell levels. Combination of a single plasma activation marker measurement (such as soluble TNF-RII) with CD4 T-cell levels improved the prognostic capability of each. A new graphic technique for presenting prognostic capability indicated that plasma soluble TNF-RII and CD4 cell levels are better prognostic factors than HIV plasma level with CD4 cells < 200 x 10(6)/l. Inexpensive tests for one of the plasma activation markers, such as soluble TNF-RII or neopterin, can be useful for evaluations of HIV disease course, especially when expensive equipment, technical expertise and funding required for flow cytometry and for HIV load measurements are not readily available.
Keywords: JOURNAL ARTICLE MULTICENTER STUDY Antigens, CD/ANALYSIS Biological Markers Cohort Studies Comparative Study CD4 Lymphocyte Count Disease Progression Homosexuality, Male Human HIV Infections/IMMUNOLOGY/*PHYSIOPATHOLOGY *HIV-1/IMMUNOLOGY Male Neopterin/ANALYSIS Prognosis Receptors, Interleukin-2/ANALYSIS Receptors, Tumor Necrosis Factor/ANALYSIS Retrospective Studies Support, U.S. Gov't, P.H.S. Viral LoadKWDjournalarticlemulticenterstudyantigens,cd/analysisbiologicalmarkerscohortstudiescomparativestudycd4lymphocytecountdiseaseprogressionhomosexuality,malehumanhivinfections/immunology/KWDphysiopathologyKWDhiv-1/immunologymaleneopterin/analysisprognosisreceptors,interleukin-2/analysisreceptors,tumornecrosisfactor/analysisretrospectivestudiessupport,uKWDsKWDgov't,pKWDhKWDsKWDviralload
990228
A9920973

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .